An interim CEO and other executive changes have been made at Durham based biopharma startup Aerami Therapeutics in the wake of the death of CEO Lisa Yanez.
“We and everyone who knew Lisa Yañez have suffered a major loss with her passing. Lisa was a passionate, authentic leader who worked shoulder to shoulder with her colleagues, always focused on bringing solutions to help people live longer and better lives," says Anne Whitaker, executive chairwoman of the company's Board of Directors.
“We and everyone who knew Lisa Yañez have suffered a major loss with her passing. Lisa was a passionate, authentic leader who worked shoulder to shoulder with her colleagues, always focused on bringing solutions to help people live longer and better lives," says Anne Whitaker, executive chairwoman of the company's Board of Directors.
Ms. Yañez brings deep category experience and will lead Aerami’s focus on cardiopulmonary disease as AER-901 (inhaled imatinib) nears initiation of Phase 2.
Aerami Therapeutics Appoints Lisa Yañez as Chief Executive Officer - read this article along with other careers information, tips and advice on BioSpace